Baseline characteristics and treatment response of HCV genotype 1 patients with previous null response that are retreated with TVR or BOC triple therapy in real world setting, Hofmann et al. . . . vorgestellt anlässlich des Liver Meeting of the American Association for the Study of Liver Diseases 2013 (AASLD) in Washington, DC, (USA).